These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25431946)

  • 41. MiRNAs and Muscle Regeneration: Therapeutic Targets in Duchenne Muscular Dystrophy.
    Aránega AE; Lozano-Velasco E; Rodriguez-Outeiriño L; Ramírez de Acuña F; Franco D; Hernández-Torres F
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921834
    [No Abstract]   [Full Text] [Related]  

  • 42. Muscle stem cells in development, regeneration, and disease.
    Shi X; Garry DJ
    Genes Dev; 2006 Jul; 20(13):1692-708. PubMed ID: 16818602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia.
    Greco S; De Simone M; Colussi C; Zaccagnini G; Fasanaro P; Pescatori M; Cardani R; Perbellini R; Isaia E; Sale P; Meola G; Capogrossi MC; Gaetano C; Martelli F
    FASEB J; 2009 Oct; 23(10):3335-46. PubMed ID: 19528256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological prospects in the treatment of Duchenne muscular dystrophy.
    Ruegg UT
    Curr Opin Neurol; 2013 Oct; 26(5):577-84. PubMed ID: 23995279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle-resident mesenchymal cells.
    Sandonà M; Consalvi S; Tucciarone L; De Bardi M; Scimeca M; Angelini DF; Buffa V; D'Amico A; Bertini ES; Cazzaniga S; Bettica P; Bouché M; Bongiovanni A; Puri PL; Saccone V
    EMBO Rep; 2020 Sep; 21(9):e50863. PubMed ID: 32754983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cloning of cDNA encoding a regeneration-associated muscle protease whose expression is attenuated in cell lines derived from Duchenne muscular dystrophy patients.
    Nakayama Y; Nara N; Kawakita Y; Takeshima Y; Arakawa M; Katoh M; Morita S; Iwatsuki K; Tanaka K; Okamoto S; Kitamura T; Seki N; Matsuda R; Matsuo M; Saito K; Hara T
    Am J Pathol; 2004 May; 164(5):1773-82. PubMed ID: 15111323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
    Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
    Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease?
    Taniguchi M; Kurahashi H; Noguchi S; Sese J; Okinaga T; Tsukahara T; Guicheney P; Ozono K; Nishino I; Morishita S; Toda T
    Biochem Biophys Res Commun; 2006 Apr; 342(2):489-502. PubMed ID: 16487936
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA approves an HDAC inhibitor for Duchenne muscular dystrophy.
    Mullard A
    Nat Rev Drug Discov; 2024 May; 23(5):329. PubMed ID: 38605117
    [No Abstract]   [Full Text] [Related]  

  • 54. The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.
    Colussi C; Berni R; Rosati J; Straino S; Vitale S; Spallotta F; Baruffi S; Bocchi L; Delucchi F; Rossi S; Savi M; Rotili D; Quaini F; Macchi E; Stilli D; Musso E; Mai A; Gaetano C; Capogrossi MC
    Cardiovasc Res; 2010 Jul; 87(1):73-82. PubMed ID: 20164117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tetraspanin CD82 is necessary for muscle stem cell activation and supports dystrophic muscle function.
    Hall A; Fontelonga T; Wright A; Bugda Gwilt K; Widrick J; Pasut A; Villa F; Miranti CK; Gibbs D; Jiang E; Meng H; Lawlor MW; Gussoni E
    Skelet Muscle; 2020 Nov; 10(1):34. PubMed ID: 33243288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
    Nik-Ahd F; Bertoni C
    Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy.
    Colussi C; Gurtner A; Rosati J; Illi B; Ragone G; Piaggio G; Moggio M; Lamperti C; D'Angelo G; Clementi E; Minetti G; Mozzetta C; Antonini A; Capogrossi MC; Puri PL; Gaetano C
    FASEB J; 2009 Jul; 23(7):2131-41. PubMed ID: 19264835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced Energetic State and Protection from Oxidative Stress in Human Myoblasts Overexpressing BMI1.
    Dibenedetto S; Niklison-Chirou M; Cabrera CP; Ellis M; Robson LG; Knopp P; Tedesco FS; Ragazzi M; Di Foggia V; Barnes MR; Radunovic A; Marino S
    Stem Cell Reports; 2017 Aug; 9(2):528-542. PubMed ID: 28735850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic Regulation of Adult Myogenesis.
    Robinson DCL; Dilworth FJ
    Curr Top Dev Biol; 2018; 126():235-284. PubMed ID: 29305001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming.
    Quattrocelli M; Zelikovich AS; Jiang Z; Peek CB; Demonbreun AR; Kuntz NL; Barish GD; Haldar SM; Bass J; McNally EM
    JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31852847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.